Similar articles for PMID: 34725231

Year	Number of Results
2015	1
2016	11
2017	26
2018	27
2019	24
2020	22
2021	15
2022	4
2024	0

1

PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy.

Calais J, Czernin J. Calais J, et al. J Nucl Med. 2021 Nov;62(11):1489-1491. doi: 10.2967/jnumed.121.263159. J Nucl Med. 2021. PMID: 34725231 Free PMC article. No abstract available.

2

Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.

Amin A, Blazevski A, Thompson J, Scheltema MJ, Hofman MS, Murphy D, Lawrentschuk N, Sathianathen N, Kapoor J, Woo HH, Chalasani V, Rasiah K, van Leeuwen PJ, Tang R, Cusick T, Stricker P, Emmett L. Amin A, et al. BJU Int. 2020 Apr;125(4):515-524. doi: 10.1111/bju.14999. Epub 2020 Feb 12. BJU Int. 2020. PMID: 31957122

3

Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer.

Meijer D, Eppinga WSC, Mohede RM, Vanneste BGL, Meijnen P, Meijer OWM, Daniels LA, van den Bergh RCN, Lont AP, Ettema RH, Oudshoorn FHK, van Leeuwen PJ, van der Poel HG, Donswijk ML, Oprea-Lager DE, Schaake EE, Vis AN. Meijer D, et al. Eur Urol Oncol. 2022 Apr;5(2):146-152. doi: 10.1016/j.euo.2022.01.001. Epub 2022 Jan 22. Eur Urol Oncol. 2022. PMID: 35074282 Free article.

4

⁶⁸Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.

von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G. von Eyben FE, et al. Eur Urol Focus. 2018 Sep;4(5):686-693. doi: 10.1016/j.euf.2016.11.002. Epub 2016 Nov 15. Eur Urol Focus. 2018. PMID: 28753806 Free article.

5

Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging.

Hofman MS, Iravani A, Nzenza T, Murphy DG. Hofman MS, et al. Urol Clin North Am. 2018 Aug;45(3):503-524. doi: 10.1016/j.ucl.2018.03.016. Epub 2018 Jun 15. Urol Clin North Am. 2018. PMID: 30031469 Review.

6

⁶⁸Ga-PSMA-PET/CT in comparison with ¹⁸F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study.

Dyrberg E, Hendel HW, Huynh THV, Klausen TW, Løgager VB, Madsen C, Pedersen EM, Pedersen M, Thomsen HS. Dyrberg E, et al. Eur Radiol. 2019 Mar;29(3):1221-1230. doi: 10.1007/s00330-018-5682-x. Epub 2018 Aug 21. Eur Radiol. 2019. PMID: 30132104

7

Efficacy, Predictive Factors, and Prediction Nomograms for ⁶⁸Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy.

Rauscher I, Düwel C, Haller B, Rischpler C, Heck MM, Gschwend JE, Schwaiger M, Maurer T, Eiber M. Rauscher I, et al. Eur Urol. 2018 May;73(5):656-661. doi: 10.1016/j.eururo.2018.01.006. Epub 2018 Jan 19. Eur Urol. 2018. PMID: 29358059

8

A Multicenter Prospective Clinical Trial of ⁶⁸Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging.

McCarthy M, Francis R, Tang C, Watts J, Campbell A. McCarthy M, et al. Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):801-808. doi: 10.1016/j.ijrobp.2019.03.014. Epub 2019 Mar 16. Int J Radiat Oncol Biol Phys. 2019. PMID: 30890448 Clinical Trial.

9

Quantitative characterisation of clinically significant intra-prostatic cancer by prostate-specific membrane antigen (PSMA) expression and cell density on PSMA-11.

Domachevsky L, Goldberg N, Bernstine H, Nidam M, Groshar D. Domachevsky L, et al. Eur Radiol. 2018 Dec;28(12):5275-5283. doi: 10.1007/s00330-018-5484-1. Epub 2018 May 30. Eur Radiol. 2018. PMID: 29846803

10

Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol.

Calais J, Zhu S, Hirmas N, Eiber M, Hadaschik B, Stuschke M, Herrmann K, Czernin J, Kishan AU, Nickols NG, Elashoff D, Fendler WP. Calais J, et al. BMC Cancer. 2021 May 7;21(1):512. doi: 10.1186/s12885-021-08026-w. BMC Cancer. 2021. PMID: 33962579 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

103 results

Results by year